Stockscreener 앱 받기
3.46
2.06%
0.07
시장 영업 전:
3.48
0.02
+0.58%
전일 마감가:
$3.39
열려 있는:
$3.4
하루 거래량:
3.57M
Relative Volume:
0.62
시가총액:
$827.16M
수익:
$116.33M
순이익/손실:
$-209.25M
주가수익비율:
-1.6321
EPS:
-2.12
순현금흐름:
$-135.49M
1주 성능:
+1.17%
1개월 성능:
-10.82%
6개월 성능:
+87.53%
1년 성능:
+93.30%
1일 변동 폭
$3.33
$3.51
1주일 범위
$3.16
$3.51
52주 변동 폭
$0.6925
$4.175
Esperion Therapeutics Inc Stock (ESPR) Company Profile
명칭
Esperion Therapeutics Inc
전화
734-887-3903
주소
3891 RANCHERO DRIVE, SUITE 150, ANN ARBOR, MI
Compare ESPR vs TAK, ZTS, HLN, TEVA, UTHR
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ESPR
Esperion Therapeutics Inc
|
3.46 | 810.43M | 116.33M | -209.25M | -135.49M | -2.12 |
|
TAK
Takeda Pharmaceutical Co Adr
|
18.28 | 57.18B | 29.85B | 776.90M | 4.35B | 0.2408 |
|
ZTS
Zoetis Inc
|
128.67 | 56.47B | 9.40B | 2.65B | 2.24B | 5.935 |
|
HLN
Haleon Plc Adr
|
11.16 | 49.16B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
34.31 | 40.03B | 17.41B | 1.43B | 1.00B | 1.2182 |
|
UTHR
United Therapeutics Corp
|
475.85 | 20.37B | 3.13B | 1.27B | 1.12B | 26.39 |
Esperion Therapeutics Inc Stock (ESPR) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-11-25 | 개시 | Piper Sandler | Overweight |
| 2024-12-18 | 개시 | Goldman | Neutral |
| 2024-12-17 | 개시 | Cantor Fitzgerald | Overweight |
| 2024-06-20 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2024-01-03 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2023-11-20 | 재개 | JP Morgan | Neutral |
| 2023-08-01 | 업그레이드 | Northland Capital | Under Perform → Market Perform |
| 2023-06-15 | 업그레이드 | BofA Securities | Underperform → Buy |
| 2023-03-16 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2023-03-16 | 다운그레이드 | Northland Capital | Market Perform → Under Perform |
| 2023-03-07 | 업그레이드 | Credit Suisse | Underperform → Neutral |
| 2023-02-27 | 재개 | BofA Securities | Neutral |
| 2023-02-24 | 업그레이드 | Jefferies | Hold → Buy |
| 2023-02-03 | 업그레이드 | Morgan Stanley | Underweight → Equal-Weight |
| 2022-08-03 | 다운그레이드 | Credit Suisse | Neutral → Underperform |
| 2022-05-05 | 업그레이드 | JP Morgan | Underweight → Neutral |
| 2022-03-10 | 개시 | H.C. Wainwright | Buy |
| 2021-10-19 | 다운그레이드 | Credit Suisse | Outperform → Neutral |
| 2021-10-14 | 다운그레이드 | Morgan Stanley | Equal-Weight → Underweight |
| 2021-05-05 | 다운그레이드 | Stifel | Buy → Hold |
| 2021-04-26 | 재개 | Credit Suisse | Outperform |
| 2021-03-11 | 개시 | Morgan Stanley | Equal-Weight |
| 2021-02-12 | 다운그레이드 | Jefferies | Buy → Hold |
| 2021-02-09 | 다운그레이드 | Goldman | Neutral → Sell |
| 2021-01-15 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2020-11-10 | 업그레이드 | Credit Suisse | Neutral → Outperform |
| 2020-09-29 | 재개 | JP Morgan | Underweight |
| 2020-08-11 | 다운그레이드 | Credit Suisse | Outperform → Neutral |
| 2020-04-01 | 재개 | BofA/Merrill | Buy |
| 2020-03-17 | 업그레이드 | Citigroup | Neutral → Buy |
| 2020-02-24 | 다운그레이드 | Northland Capital | Outperform → Market Perform |
| 2020-02-14 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2019-09-16 | 업그레이드 | Goldman | Sell → Neutral |
| 2019-05-29 | 다운그레이드 | Goldman | Neutral → Sell |
| 2019-05-06 | 업그레이드 | BofA/Merrill | Underperform → Neutral |
| 2019-04-26 | 업그레이드 | Goldman | Sell → Neutral |
| 2019-03-13 | 업그레이드 | JP Morgan | Underweight → Neutral |
| 2019-01-07 | 재확인 | Needham | Strong Buy |
| 2018-12-13 | 개시 | Goldman | Sell |
| 2018-10-29 | 업그레이드 | Northland Capital | Market Perform → Outperform |
| 2018-10-16 | 개시 | BTIG Research | Buy |
| 2018-08-17 | 업그레이드 | Citigroup | Neutral → Buy |
| 2018-07-11 | 다운그레이드 | Northland Capital | Outperform → Market Perform |
| 2018-05-03 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2018-05-02 | 다운그레이드 | BofA/Merrill | Buy → Underperform |
모두보기
Esperion Therapeutics Inc 주식(ESPR)의 최신 뉴스
New hires at Esperion receive 40,200 restricted stock units as hiring incentive - Stock Titan
Market Trends: How does Esperion Therapeutics Inc. score in quality rankings2025 Key Highlights & Weekly Chart Analysis and Trade Guides - baoquankhu1.vn
What is the next catalyst for Esperion Therapeutics IncWeekly Investment Report & Expert Curated Trade Setups - baoquankhu1.vn
Weekly Trades: How does Esperion Therapeutics Inc. score in quality rankingsMarket Risk Report & Daily Oversold Stock Bounce Ideas - baoquankhu1.vn
Esperion Therapeutics Inc. (ESPR) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Zacks Research Issues Optimistic Forecast for ESPR Earnings - MarketBeat
Zacks Research Analysts Reduce Earnings Estimates for ESPR - MarketBeat
Esperion Therapeutics (NASDAQ:ESPR) Raised to "Buy" at Wall Street Zen - MarketBeat
How The New Price Target Is Shaping The Story For Esperion Therapeutics (ESPR) - Yahoo Finance
3,000,000 Shares in Esperion Therapeutics, Inc. $ESPR Bought by AIGH Capital Management LLC - MarketBeat
Esperion Therapeutics (NASDAQ:ESPR) Downgraded to Hold Rating by Wall Street Zen - MarketBeat
Analyst Downgrade: What are Esperion Therapeutics Incs technical support levelsInflation Watch & Free Reliable Trade Execution Plans - baoquankhu1.vn
Esperion Therapeutics general counsel sells $4.9k in stock By Investing.com - Investing.com Australia
Esperion Therapeutics, Inc. (NASDAQ:ESPR) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Esperion Therapeutics general counsel sells $4.9k in stock - Investing.com
Esperion Therapeutics warns of winter cholesterol risk - Traders Union
Is Esperion Therapeutics Inc. stock a falling knife or bargain buyJuly 2025 Update & Stepwise Trade Signal Guides - bollywoodhelpline.com
Winners Losers: Is Esperion Therapeutics Inc a defensive stockMarket Sentiment Report & Entry and Exit Point Strategies - baoquankhu1.vn
Esperion Therapeutics (NASDAQ:ESPR) Shares Gap DownShould You Sell? - MarketBeat
What is HC Wainwright's Estimate for ESPR FY2025 Earnings? - MarketBeat
Esperion Seeks Acquisitions - marketscreener.com
How does Esperion Therapeutics Inc score in quality rankingsDip Buying & Safe Entry Trade Signal Reports - baoquankhu1.vn
Highs Report: What is Esperion Therapeutics Incs TAM Total Addressable MarketJuly 2025 Sector Moves & Free Fast Gain Swing Trade Alerts - baoquankhu1.vn
HC Wainwright Issues Optimistic Estimate for ESPR Earnings - MarketBeat
Esperion Therapeutics Faces Financial Challenges Amid Market Uncertainty - StocksToTrade
Esperion Therapeutics (NASDAQ:ESPR) Shares Down 6.3%Here's Why - MarketBeat
Esperion Projects FY2025 U.S. Net Product Sales Growth Of 35% To 38%; Stock Up - Nasdaq
Esperion Reports $156-$160 Million in 2025 Sales, Unveils Vision 2040 Strategy - Intellectia AI
Esperion Reports Significant Growth in Preliminary 2025 Financial Results and Unveils Vision 2040 Growth Strategy - Quiver Quantitative
Esperion reports $156 to $160 million in preliminary full-year 2025 U.S. net product sales - marketscreener.com
Esperion Provides Business Update at 44th Annual J.P. Morgan Healthcare Conference - The Manila Times
Cholesterol drug maker lays 2040 plan as new pills target 60% LDL drop - Stock Titan
Why Esperion Therapeutics Inc stock attracts global investorsMarket Movers & Community Verified Trade Signals - moha.gov.vn
Esperion Therapeutics Stock Hits Near 1-Year High As Wall Street Sees Strong Risk-Reward Play On Demand For Cholesterol Drug - MSN
Can Esperion Therapeutics Inc. stock sustain institutional interest2025 Market Sentiment & AI Driven Price Predictions - Улправда
Will Esperion Therapeutics Inc. (0ET) stock beat growth indexesQuarterly Performance Summary & Trade Opportunity Analysis - ulpravda.ru
Is Esperion Therapeutics Inc. (0ET) stock considered safe havenJuly 2025 Chart Watch & Verified Momentum Stock Watchlist - ulpravda.ru
Merger Talk: Is Esperion Therapeutics Inc. (0ET) stock considered safe haven2025 Winners & Losers & Reliable Momentum Entry Alerts - Улправда
Esperion Therapeutics (NASDAQ:ESPR) Sets New 12-Month HighHere's Why - MarketBeat
Esperion Therapeutics gets Untitled Letter from FDA over Nexlizet ad - Medical Marketing and Media
How Esperion Therapeutics Inc. stock performs in rising dollar environmentQuarterly Profit Report & Technical Buy Zone Confirmations - Улправда
Free Technical Research Reports on Biotech Stocks -- Epizyme, Esperion Therapeutics, Exelixis, and Grifols - ADVFN
Will Esperion Therapeutics Inc. (0ET) stock outperform value peersVolume Profile Analysis & Double Digit Returns - Улправда
Esperion Sets Its Sights on New Areas While Maintaining Commitment to Cardiovascular Health - MedCity News
Esperion Therapeutics chief commercial officer sells $277 in stock - MSN
Esperion to Participate in Upcoming 44th Annual J.P. Morgan Healthcare Conference - The Manila Times
What analysts say about Esperion Therapeutics Inc stockMarket Volatility Update & Rapid Wealth Accumulation - earlytimes.in
Why Is Esperion Therapeutics Stock Sinking Premarket Today? - MSN
Esperion Therapeutics (NASDAQ:ESPR) Upgraded by Wall Street Zen to "Buy" Rating - MarketBeat
Esperion Therapeutics (NASDAQ:ESPR) Shares Gap UpWhat's Next? - MarketBeat
Is Esperion Therapeutics Inc a good long term investmentGlobal Trade Effects & Free Rapid Wealth Building - earlytimes.in
Esperion Therapeutics Inc (ESPR) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.21%
0.15%
자본화:
|
볼륨(24시간):